ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2695

Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry

Kate Homer1, Benjamin Brennan2, Shervin Assassi3, Elana J. Bernstein4, Flavia V. Castelino5, Robyn T. Domsic6, Jessica K. Gordon7, Faye N. Hant8, Monique Hinchcliff9, Ami A. Shah10, Victoria Shanmugam11, Virginia D. Steen12, Veronica J. Berrocal13, Melanie Hemmrich14, Tracy M. Frech15 and Dinesh Khanna16, 1Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, 2School of Public Health, University of Michigan, Ann Arbor, MI, 3University of Texas McGovern Medical School, Houston, TX, 4Rheumatology, Columbia University, New York, NY, 5Rheumatology, Harvard Medical School, Boston, MA, 6Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 9Rheumatology, Northwestern University, Chicago, IL, 10Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 11Rheumatology, The George Washington University, Washington, DC, 12Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 13Div of Rheumatology, University of Michigan, Ann Arbor, MI, 14Bayer AG, Wuppertal, Germany, 15Division of Rheumatology, University of Utah, Salt Lake City, UT, 16Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Early diffuse cutaneous systemic sclerosis (dcSSc) carries a high morbidity and mortality, predominantly due to internal organ involvement. The purpose of this study was to investigate the time to event of new onset of visceral organ involvement and all-cause mortality in early dcSSc participants in an ongoing US multicenter registry (Prospective Registry of Early Systemic Sclerosis [PRESS]).

Methods: Inclusion criteria include a diagnosis of dcSSc and a disease duration of ≤ 2 years calculated from the date of onset of first non-Raynaud’s phenomenon symptom. Organ involvement was defined as new involvement or worsening during follow up visits— 1) absolute increase in mRSS of ≥ 4 units or 20%, 2) an absolute decline of FVC % of ≥ 10%; 3) PH on RHC; 4) LVEF of ≤ 45% on echo; 4) scleroderma renal crisis; or 5) all-cause mortality. We reported number of participants experiencing organ involvement during the course of the study via frequency tables and characterized the distribution of events through plots of the cumulative proportion of participants experiencing each event by time. Confidence intervals in the cumulative proportion plots were derived via bootstrap method.

Results: The cohort consisted of 239 participants from 11 US SSc centers at baseline with median follow-up of 414 days (IQR=112-922 days). The baseline mean age for the cohort was 50.1 years, disease duration was 1.3 years, HAQ-DI score was 0.82, 71.1% were female, and 76.2% were white. In this cohort, 199 (83.3%) were treated with immunomodulatory therapies during the course of the study (82.0% during the first year) including 63.2% on mycophenolate mofetil, 20.9% on methotrexate, 5.0% on cyclophosphamide, 3.3% on D-penicillamine, 16.3% on hydroxychloroquine, and 2.1% on azathioprine (percentage is greater than 82.0% as some participants were on multiple therapies at a single time-point and/or during the study). Survival function plots showed that 75 of 231 (32.5%) participants showed progressive skin fibrosis, 27 of 192 (14.1%) showed ≥ 10% worsening of FVC%, 4 of 199 (2.0%) showed LVEF of ≤ 45%, 12 of 239 (5.0%) had new onset scleroderma renal crisis, 5 of 239 (2.1 %) had PH on RHC, and 14 of 239 (5.9%) died during the course of the study (Figure); 11 of the 14 deaths were considered to be related to SSc.

Conclusion: Despite immunomodulatory therapy, a high proportion of early dcSSc patients experience worsening of mRSS and lung function and mortality within 2 years of dcSSc diagnosis. There are ongoing vascular-predominant complications over the course of the disease, consistent with published literature [1]. This data supports an ongoing need to identify novel therapies for dcSSc.

1. Nihtyanova SI. Arthritis & rheumatology. 2014.

 ADDIN EN.REFLIST


Disclosure: K. Homer, None; B. Brennan, None; S. Assassi, None; E. J. Bernstein, Genentech, Inc., 5; F. V. Castelino, Genentech, Inc.; Boehringer Ingelheim, 5; R. T. Domsic, None; J. K. Gordon, None; F. N. Hant, None; M. Hinchcliff, None; A. A. Shah, Bristol-Myers Squibb, 5; V. Shanmugam, None; V. D. Steen, Bayer, 2, 5,Reata, 2; V. J. Berrocal, None; M. Hemmrich, Bayer, 3; T. M. Frech, None; D. Khanna, Eicos Sciences, 1,Pfizer, Inc., 2,Horizon, 2,BMS, 2,Actelion, 5,Bayer, 5,Bayer, 2,Corbus, 5,Cytori, 5,EMD Serono, 5,Genentech, Inc., 5,Sanofi-Aventis, 5,GSK, 5,Boehringer Ingelheim, 5.

To cite this abstract in AMA style:

Homer K, Brennan B, Assassi S, Bernstein EJ, Castelino FV, Domsic RT, Gordon JK, Hant FN, Hinchcliff M, Shah AA, Shanmugam V, Steen VD, Berrocal VJ, Hemmrich M, Frech TM, Khanna D. Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/progressive-skin-fibrosis-internal-organ-involvement-and-all-cause-mortality-in-an-early-diffuse-cutaneous-systemic-sclerosis-united-states-multicenter-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/progressive-skin-fibrosis-internal-organ-involvement-and-all-cause-mortality-in-an-early-diffuse-cutaneous-systemic-sclerosis-united-states-multicenter-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology